PLAU, plasminogen activator, urokinase, 5328

N. diseases: 439; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019562
Disease: Von Hippel-Lindau Syndrome
Von Hippel-Lindau Syndrome 		0.010 Biomarker disease BEFREE We determined the role of the VHL tumor suppressor gene in the regulation of the uPA system in RCC. 10485495 1999
CUI: C0042510
Disease: Ventricular Fibrillation
Ventricular Fibrillation 		0.300 Biomarker disease CTD_human Ventricular fibrillation after intrapleural urokinase. 9083243 1997
CUI: C0042487
Disease: Venous Thrombosis
Venous Thrombosis 		0.300 Therapeutic phenotype CTD_human Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis. 3488869 1986
CUI: C0042487
Disease: Venous Thrombosis
Venous Thrombosis 		0.300 Therapeutic phenotype CTD_human Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. 15557913 2004
CUI: C0042487
Disease: Venous Thrombosis
Venous Thrombosis 		0.300 Therapeutic phenotype CTD_human Fibrinogenolysis and fibrinolysis in normal volunteers and patients with thrombosis after infusion of urokinase. 3161212 1985
CUI: C0042487
Disease: Venous Thrombosis
Venous Thrombosis 		0.300 Therapeutic phenotype CTD_human Controlled multicenter pilot study of urokinase- heparin and streptokinase in deep vein thrombosis. 6359570 1983
CUI: C0472387
Disease: Vasogenic Cerebral Edema
Vasogenic Cerebral Edema 		0.300 Biomarker phenotype CTD_human Massive cerebral edema after recanalization post-thrombolysis. 11677890 2001
CUI: C0750969
Disease: Vasogenic Brain Edema
Vasogenic Brain Edema 		0.300 Biomarker phenotype CTD_human Massive cerebral edema after recanalization post-thrombolysis. 11677890 2001
CUI: C0042386
Disease: Vasculitis, Hemorrhagic
Vasculitis, Hemorrhagic 		0.300 Therapeutic phenotype CTD_human Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy. 9002298 1996
CUI: C0042386
Disease: Vasculitis, Hemorrhagic
Vasculitis, Hemorrhagic 		0.300 Therapeutic phenotype CTD_human Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schönlein nephritis. 12671112 2003
CUI: C1096458
Disease: Vascular occlusion
Vascular occlusion 		0.010 Biomarker disease BEFREE Whether high concentrations of t-PA, u-PA and PAI 1 antigen can predict future vascular occlusion in children with APCR requires a more extensive multicentre study. 9083758 1997
CUI: C0042373
Disease: Vascular Diseases
Vascular Diseases 		0.010 AlteredExpression group BEFREE In SSc, the downregulation of miR-193b induces the expression of uPA, which increases the number of vascular smooth muscle cells in an uPAR-independent manner and thereby contributes to the proliferative vasculopathy with intimal hyperplasia characteristic for SSc. 25384965 2016
CUI: C4721509
Disease: Usual Interstitial Pneumonia
Usual Interstitial Pneumonia 		0.300 Therapeutic disease CTD_human The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy. 18491991 2008
CUI: C0042029
Disease: Urinary tract infection
Urinary tract infection 		0.010 AlteredExpression group BEFREE These data suggest that UTI significantly down-regulates tumor cell uPA mRNA expression and protein secretion, and that UTI binding to the cells is necessary to exert the UTI's action. 11018722 2000
CUI: C0041696
Disease: Unipolar Depression
Unipolar Depression 		0.010 GeneticVariation disease BEFREE Depression and fatigue during chronic IFN-α administration were associated with alterations in the expression (OAS2) and transcriptional control (CREB/ATF) of genes linked to behavioral disorders including CFS and major depression, further supporting an immune contribution to these diseases. 22152193 2012
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis 		0.100 GeneticVariation disease GWASCAT Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. 26974007 2016
CUI: C1519666
Disease: Tumor-Associated Vasculature
Tumor-Associated Vasculature 		0.010 Biomarker disease BEFREE A bispecific immunotoxin (IT) called DTAT13 was synthesized in order to target simultaneously the urokinase-type plasminogen activator receptor (uPAR)-expressing tumor neovasculature and IL-13 receptor expressing glioblastoma cells with the goal of intratumoral administration for brain tumors. 15047912 2004
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.010 Biomarker phenotype BEFREE MV-m-uPA targeted murine tumor vasculature after systemic administration, as shown by dual (CD31 and MV-N) staining of tumor capillaries in the MDA-MB-231 model. 19208845 2009
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Urokinase-type plasminogen activator (uPA) is a serine protease that is involved in cancer progression, especially invasion and metastasis including prostate cancer. uPA activation is mediated by transactivation of uPAR and epidermal growth factor receptor (EGF-R) in prostate cancer progression. 21308698 2011
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE A large body of evidence support that among the various components of the PA system, urokinase-type plasminogen activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 and -2 (PAI-1 and PAI-2) play a major role in tumor progression and metastasis. 29484286 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Urokinase-type plasminogen activator (u-PA) contributes to tumor progression in prostate cancer (CaP). 11676474 2001
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Only full length uPAR mediates tumor progression. 25003596 2014
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Although, uPA is dysregulate in tumor progression, its expression is finely regulated at both enzymatic activity and at protein expression as well, which allow cancer cells efficiently survive, proliferate, and spread into neighbouring tissues and distant organs. 28820062 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Urokinase-type plasminogen activator (uPA) is a serine protease that is causally involved in cancer progression, especially invasion and metastasis. 12023852 2002
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Cancer invasion and metastasis are highly complex processes and a serine protease urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been postulated to play a central role in the mediation of cancer progression. 17075310 2006